Relevant bibliographies by topics / 621.3 (09) (04)

Contents

  1. Journal articles
  2. Book chapters
  3. Conference papers

Academic literature on the topic '621.3 (09) (04)'

Author: Grafiati
Published: 30 May 2022
Last updated: 31 May 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '621.3 (09) (04).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "621.3 (09) (04)"

1

Xi, Jing, Kathleen Harnden, Jingqin Luo, Greg S. Call, Elizabeth Mauer, Karyn Ronski, Cynthia X. Ma, and Neil Vasan. "Abstract P3-09-04: Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations." Cancer Research 82, no. 4_Supplement (February 15, 2022): P3–09–04—P3–09–04. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-09-04.

Full text
Abstract:
Abstract Background: Alpelisib and fulvestrant are used as a combination treatment option for postmenopausal PIK3CA-mutated, hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced or metastatic breast cancer (a/mBC) patients. However, despite the presence of activating mutations in PIK3CA, the majority of patients do not derive benefit, or ultimately progress while on alpelisib therapy. Here, we investigate the genomic landscape of PIK3CA-mutated, HER2- a/mBC using next-generation sequencing (NGS) to provide insight into possible mechanisms of therapeutic resistance to alpelisib/fulvestrant and to identify potential targetable pathways. Methods: We utilized the Tempus LENS platform to retrospectively analyze de-identified NGS data from 2,918 a/mBC patients with formalin-fixed, paraffin-embedded tumor biopsies sequenced using the Tempus|xT solid tumor assay (DNA-seq of 595-648 genes at 500x coverage; full transcriptome RNA-seq). Mutations identified included germline and/or somatic single nucleotide variants, insertions/deletions and copy number variations (gains defined as ≥8 copies). We used curated clinical data to determine HER2 and hormone receptor (ER/PR) status. Results: Among 2,918 a/mBC patients, we identified somatic mutations in PIK3CA in 782 (26.8%). Within these tumors, 629 (80.4%) had one of the 11 mutations currently included in the alpelisib companion diagnostic, and we focused on this population (here defined as mut-PIK3CA). Of these 629, 546 (86.8%) were HER2-, with 176 (32.3%) and 370 (67.7%) derived from primary and metastatic tumors, respectively. Cases were further classified as HR+ (defined as ER+ or PR+) or triple negative (TNBC). While the majority of mutPIK3CA samples were identified in HR+ disease, 10% of the cases occurred in TNBC. Within the mutPIK3CA cohort, tumor mutational burden high (TMB-H; defined as ≥10 mutations/MB) was detected in 11.5% of samples, while microsatellite instability high (MSI-H) was detected in 0.5%. MSI-H was detected at a higher frequency in TNBC compared to HR+. Overall, the most commonly co-mutated genes among mutPIK3CA, HER2- samples were TP53 (34.6%), CDH1 (21.6%), ESR1 (12.3%), KMT2C (11%), MAP3K1 (9.5%), ARID1A (8.1%), PTEN (6.8%), GATA3 (6.6%), NF1 (5.9%), and TBX3 (5.9%) among others (Table 1); some of these genes have previously been implicated in resistance to endocrine therapy or PI3K inhibitor. In addition, in HR+ disease, metastatic samples had a higher frequency of mutations in genes implicated in endocrine resistance, such as ESR1 (18.7% vs 1.9%), ERBB2 (3.3% vs 2.6%), NF1 (6.8% vs 2.6%), compared to primary tumors. We also identified copy number gains (CNG) in several cell cycle genes, including: CCND1 (15.2%), CDK4 (2.7%), and AURKA (2.6%) (Table 1). Finally, further analyses at the transcript-level are the subject of on-going research. Conclusions: Our study highlights that there is substantial genomic heterogeneity among mutPIK3CA, HER2- a/mBCs. Across a series of comparisons between primary and metastatic samples, as well as HR+ and TNBC subtypes, we identified a number of co-mutations that occur alongside mutPIK3CA and which could be potentially exploited by targeted therapies. Future studies are needed to assess the prognostic/predictive role of these and other candidate gene alterations. Table 1. Genomic features of mutPIK3CA, HER2– a/mBCPrimaryMetastaticTotalAny PIK3CA Mutation1255527782mutPIK3CA2204425629HER2– (n=176)HER2– (n=370)546HR+ HER2– 154 (88%)TNBC 22 (12%)HR+ HER2– 337 (91%)TNBC 33 (9%)TMB-H16 (10.3%)2 (9.1%)41 (12%)4 (12%)63 (11.5%)MSI-H1 (0.6%)1 (4.5%)0 (0%)1 (3.0%)3 (0.5%)Co-mutations (mutPIK3CA): n (%)TP5347 (30.5%)14 (63.6%)101 (30%)27 (81.8%)189 (34.6%)CDH137 (24%)1 (4.5%)75 (22.3%)5 (15.2%)118 (21.6%)KMT2C17 (11%)1 (4.5%)40 (11.9%)2 (6.1%)60 (11%)MAP3K117 (11%)1 (4.5%)31 (9.2%)1 (3%)50 (9.2%)ARID1A15 (9.7%)0 (0%)26 (7.7%)2 (6.1%)43(7.9%)PTEN12 (7.8%)1 (4.5%)21 (6.2%)3 (9.1%)37 (6.8%)GATA311 (7.1%)0 (0%)23 (6.8%)2 (6.1%)35 (6.6%)TBX311 (7.1%)1 (4.5%)19 (5.6%)1 (3%)32 (5.9%)NCOR12 (1.3%)1 (4.5%)18 (5.3%)0 (0%)21 (3.8%)FOXA17 (4.5%)2 (9.1%)10 (3%)1 (3%)20 (3.7%)MAP2K41 (0.6%)1 (4.5%)12 (3.6%)1 (3%)15 (2.7%)ESR13 (1.9%)0 (0%)63 (18.7%)1 (3%)67 (12.3%)PIK3R13 (1.9%)0 (0%)4 (1.2%)0 (0%)7 (1.3%)AKT11 (0.6%)0 (0%)1 (0.6%)0 (0%)2 (0.4%)RB15 (3.2%)1 (4.5%)8 (2.4%)1 (3%)15 (2.7%)NF14 (2.6%)3 (13.6%)23 (6.8%)2 (6.1%)32 (5.9%)ERBB24 (2.6%)4 (18.2%)11 (3.3%)2 (6.1%)21 (3.8%)CCND1 CNG22 (14%)0 (0%)61 (18%)0 (0%)83 (15.2%)AURKA CNG3 (1.9%)0 (0%)11 (3.3%)0 (0%)14 (2.6%)CDK4 CNG5 (3.2%)1 (4.5%)7 (2.1%)1 (3.0%)14 (2.6%)1any somatic variant detected in PIK3CA2somatic PIK3CA mutations among the 11 currently included in the alpelisib companion diagnostic (C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y) Citation Format: Jing Xi, Kathleen Harnden, Jingqin Luo, Greg S. Call, Elizabeth Mauer, Karyn Ronski, Cynthia X. Ma, Neil Vasan. Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-09-04.
APA, Harvard, Vancouver, ISO, and other styles
2

Rodríguez-Arnao, J., G. Yarwood, C. Ferguson, J. Miell, C. J. Hinds, and R. J. M. Ross. "Reduction in circulating IGF-I and hepatic IGF-I mRNA levels after caecal ligation and puncture are associated with differential regulation of hepatic IGF-binding protein-1, -2 and -3 mRNA levels." Journal of Endocrinology 151, no. 2 (November 1996): 287–92. http://dx.doi.org/10.1677/joe.0.1510287.

Full text
Abstract:
Abstract Sepsis is characterized by a severe shift in metabolism, characterized by low IGF-I levels. We have studied the influence of caecal ligation and puncture (CLP) on the levels of circulating IGF-I and hepatic IGF-I and IGF-binding protein (IGFBP)-1, -2 and -3 mRNA in adult male Wistar rats (n=12) and compared it with sham-operated rats (n=6). In order to exclude anorexia-induced changes we also studied animals pair-fed to both groups. IGF-I levels were measured by RIA. Steady-state hepatic IGF-I, IGFBP-1, IGFBP-2 and IGFBP-3 mRNA levels were measured by Northern blot analysis using specific rat cDNA probes. Food intake averaged 13·0 ± 2·0 g/day in the sham-operated rats fed ad libitum during the study period, with a sharp decline in food intake in the CLP animals (2·3 ± 1·3 g/day). After CLP, there was a significant reduction in circulating IGF-I levels (467·2 ± 50·9 μg/l) compared with sham-operated animals (924·0 ± 75·3 μg/l; P=0·04) or those pair-fed to the CLP rats (612·5 ± 52·9 μg/l; P=0·04). Total hepatic IGF-I mRNA levels were significantly reduced (2·57 ± 0·05 densitometric units (DU)) after CLP compared with the sham-operated group (2·71 ± 0·04; P=0·04), or their pair-fed controls (2·75 ± 0·08 DU; P<0·05). Hepatic IGFBP-3 mRNA levels were lower after CLP (0·37 ± 0·04 DU) than in the sham-operated animals (0·66 ± 0·09 DU; P=0·04) or their pair-fed controls (0·61 ± 0·05 DU; P=0·04). On the other hand, hepatic IGFBP-2 mRNA levels were increased after CLP (0·91 ± 0·11 DU) compared with sham-operated animals (0·28 ± 0·06 DU; P=0·01) or with their pair-fed controls (0·22 ± 0·22; P=0·01), as were hepatic IGFBP-1 mRNA levels (CLP animals 0·95 ± 0·11 DU; sham-operated 0·30 ± 0·04 DU, P=0·01; pair-fed 0·30 ± 0·02 DU, P=0·01). No significant difference between sham-operated animals and their pair-fed controls was observed in circulating IGF-I levels (888·0 ± 109·3 μg/l; P=not significant (N.S.)), hepatic mRNA levels for IGF-I (2·72 ± 0·06 DU; P=N.S), IGFBP-3 (0·71 ± 0·07 DU; P=N.S.), IGFBP-2 (0·25 ± 0·07 DU; P=N.S.) or IGFBP-1 (0·27 ± 0·06 DU; P=N.S.). In summary, after CLP there was a reduction in both circulating and hepatic IGF-I mRNA levels associated with a specific and differential regulation of hepatic IGFBP-1, -2 and -3 mRNA levels. Although we cannot eliminate a possible effect of surgical stress combined with malnutrition, our results suggest that these changes are a specific effect of sepsis rather than simply a result of surgical stress or poor nutrition alone. Journal of Endocrinology (1996) 151, 287–292
APA, Harvard, Vancouver, ISO, and other styles
3

Lawson, Lovett, Mohammed A. Yassin, Alex N. Onuoha, Andrew Ramsay, Rachel R. M. Anderson de Cuevas, Sally Theobald, Peter D. O. Davies, and Luis E. Cuevas. "Yield of Smear Microscopy and Radiological Findings of Male and Female Patients with Tuberculosis in Abuja, Nigeria." Tuberculosis Research and Treatment 2010 (2010): 1–5. http://dx.doi.org/10.1155/2010/241659.

Full text
Abstract:
Objective. To describe the yield of smear-microscopy and radiological findings by male and female patients with symptoms of tuberculosis in Abuja, Nigeria.Methods. Patients ≥15 years old with cough for >3 weeks submitted 3 sputum samples for smear microscopy. One specimen was cultured using MGIT-960. All patients had lung X-rays and screened for HIV.Results. were more likely to be smear-positive than females (262/774 [34%] and 137/547 [25%],P<.01), but similar proportions of males and females were culture-positive (437/691 [63%] and 294/495 [59%],P=.09). 317/626 (50.6%) males and 249/419 (59.4%) females were HIV-positive (P<.005). Among culture-positives patients, HIV-infected males were less likely to have positive smears than HIV-negative males (49.2% versus 66%,P=.001). Among females, smear positivity did not vary with HIV (46.4% for HIV-positive and 52.9% for HIV-negative,P=.38). Of 274 culture-confirmed TB cases, 226 (82.5%) had cavities, and 271 (99%) had ≥1 lung areas affected. HIV-positive males were more likely to have lung cavities than HIV-positive females (85% versus 69%,P<.04) and to have ≥3 lung areas affected (P=.03).Conclusion. Differences in the yield of smear-microscopy, culture and X-rays on presentation are due to several factors including HIV coinfection and gender.
APA, Harvard, Vancouver, ISO, and other styles
4

Asiedu, F. H. K., and S. K. Karikari. "Energy and protein content and intake by stall-fed lambs of pure and mixed swards of Centrosema pubescens Benth., Pueraria phaseoloides Benth. and Brachiaria mutica Stapf. under a mango plantation." Journal of Agricultural Science 104, no. 1 (February 1985): 47–59. http://dx.doi.org/10.1017/s0021859600042970.

Full text
Abstract:
SummaryPure and mixed swards of Centrosema pubescens (centro), Pueraria phaseoloides (puero) and Brachiaria mutica (para grass) established under a 12-year-old mango plantation were sampled at 6-week intervals for 2 years to determine crude-protein (CP) content, dry-matter (D.M.) and CP yields and apparent digestible energy and apparent digestible crude-protein (DCP) contents. Daily dry-matter intake (DMI) and apparent digestible energy and digestible crude-protein intakes (DEI and DCPI), as well as live-weight gain (LWG) by 11·5 kg penned West African cross-bred weaner lambs, were also determined.The pure legumes were better than the mixed swards in respect of CP (mean: 22·1, 18·8, 14·4 and 13·8% for centro, puero, centro-para grass and puero-para grass respectively) and DCP (mean: 16·2, 13·4, 10·4 and 10·0% respectively) contents, and daily DMI (mean: 50·8, 49·7, 41·8 and 41·3 g/kg W0·75 respectively), DEI (mean: 562, 531, 418 and 410 kj/kg W075 respectively) and DCPI (mean: 8·09, 6·55, 4·04 and 3·94 g/kg W0·75 respectively). On the other hand the legume-grass mixed swards, especially puero-para grass, were superior to the corresponding pure-legume swards with regard to D.M. yield (mean: 11·90, 7·69, 7·13 and 4·54 t/hafor puero-para grass, centro-para grass, puero and centro respectively) and CP yield(mean: 1·62,1·09, 1·32 and 0·99 t/ha respectively). The pure-legume stands gave the highest LWG per lamb (mean: 45·7, 3·89, 2·63 and 25·3 g/day for centro, puero, centro–para grass and puero-para grass respectively) but it was estimated that the legume-grass mixed swards would give higher returns in terms of lamb LWG on forages harvested per unit sward area than the corresponding pure-legume cover.It was concluded that legume-grass covers would be preferred to all-legume covers if livestock were to be integrated into tree crop farming systems. However, the choice of companion grass would have to be given proper consideration as shade-intolerant grass species, such as para grass, would detract from profit maximization.
APA, Harvard, Vancouver, ISO, and other styles
5

Le Cesne, Axel, Jean-Yves Blay, Binh Bui Nguyen, Olivier Bouche, Julien Domont, Angela Cioffi, Julie Le Boulicaut, Alain Moussy, Olivier Hermine, and Antoine Adenis. "Masitinib in imatinib-naive advanced gastrointestinal stromal tumor (GIST): Five-year follow-up of the French Sarcoma Group phase II trial." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 10089. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10089.

Full text
Abstract:
10089 Background: Masitinib is a tyrosine kinase inhibitor that in vitro has greater activity and selectivity than imatinib against KIT. This multicenter, open label, phase 2 study evaluated efficacy and safety of masitinib as a first-line treatment of advanced GIST. Initial results with a median follow-up of 34 months, were previously reported in EJC 2010. We present here 5-year follow-up data from the same series with updated safety and survival data. Methods: Imatinib-naïve patients (pts) with inoperable, advanced GIST received oral masitinib (7.5 mg/kg/day) until progression, refusal or toxicity. Results: Thirty pts with a median age of 58 years (60% of males) were included from 06/2005 to 04/2007 in 5 institutions. At the cut-off date of 13/09/2011, 7/30 pts (23%) were still under treatment with median follow-up of 65 months and the median overall survival (OS) had not yet been reached (NR). The 5-year OS rate was 61.5% (95% CI [41.1;76.6]) (see Table). Among patients with confirmed KIT exon 11 mutation, 8/9 pts (89%) were still alive with one pt having died from non-treatment related causes (surgical complication) following a complete response while receiving masitinib. No additional progressions have been reported giving a total of 14 events (13 progressions and 1 death). Updated median PFS was 41.3 months (95% CI [17.5;53.8]).No additional grade 3/4 adverse events have been reported. Conclusions: Long term results of masitinib confirm an interesting activity with prolonged PFS and OS. The median PFS rate in masitinib compares very favorably to that of imatinib, which is reported as 18 months (JCO 26:626, 2008). The 5-year OS rates for masitinib in the overall and exon 11 populations also compare favorably to imatinib, both of which are reported at ≤50% for imatinib (JCO 26:626, 2008; JCO 28:1247, 2010). These results support the head to head comparison with imatinib in the currently ongoing phase 3 randomized clinical trial in first line advanced GIST pts. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
6

Gargallo, L., J. Vaamonde, R. Ibáñez, M. A. Del Real, A. Hernandez, and M. Gudín. "3-09-04 Early focal cerebral injury: Brain plasticity." Journal of the Neurological Sciences 150 (September 1997): S153. http://dx.doi.org/10.1016/s0022-510x(97)85595-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Plekhanova, O., Y. Parfyonova, M. Solomatina, O. Viborov, P. Bashtrikov, A. Brooks, B. Berk, and V. Tkachuk. "M.621 Novel interplay of fibrinolytic system and oxidative stress in regulation of arterial remodelling." Atherosclerosis Supplements 5, no. 1 (April 2004): 144. http://dx.doi.org/10.1016/s1567-5688(04)90619-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

PLEKHANOVA, O. "M.621 Novel interplay of fibrinolytic system and oxidative stress in regulation of arterial remodelling." Atherosclerosis 5, no. 1 (April 2004): 144. http://dx.doi.org/10.1016/s0021-9150(04)90619-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Roux, L., G. Thierry, E. Chazalon, R. Coste, S. Pommier, and F. Meyer. "621 La greffe de muqueuse palatine pour allonger la lamelle postérieure en paupière inférieure : à propos de quatre observations." Journal Français d'Ophtalmologie 32 (April 2009): 1S186. http://dx.doi.org/10.1016/s0181-5512(09)73745-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Martinez de Posadas, M. del C., and H. Liste. "5-09-04 Children's neuromuscular diseases, (prevalence in neuromuscular section during 3 years)." Journal of the Neurological Sciences 150 (September 1997): S290. http://dx.doi.org/10.1016/s0022-510x(97)86303-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "621.3 (09) (04)"

1

"E-04-3." In CESBP Central European Symposium on Building Physics / BauSIM 2016., edited by John Grunewald, 621–28. Fraunhofer IRB Verlag, 2016. http://dx.doi.org/10.51202/9783816797982-621.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Brighenti, Agenor. "A TRANSCENDÊNCIA COMO ÉTICA: ELEMENTOS EPISTEMOLÓGICOS DE UMA QUESTÃO ABERTA E COMPLEXA." In Cordeirio de Deus: Festschrift em homenagem a Luiz Carlos Susin, 101–12. Editora Fundação Fênix, 2019. http://dx.doi.org/10.36592/978-65-81110-09-3-04.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "621.3 (09) (04)"

1

Khoury, Katia, Antoinette Tan, Andrew Elliott, Joanne Xiu, Zoran Gatalica, Arielle L. Heeke, Claudine Isaacs, et al. "Abstract P4-09-04: Prevalence of phosphatidylinositol-3-kinase (PI3K) pathway alterations and co-alteration of other markers in breast cancer." In Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.sabcs19-p4-09-04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Viale, G., L. Slaets, F. de Snoo, Veer L. van't, E. Rutgers, M. Piccart, J. Bogaerts, et al. "Abstract P3-05-02: Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) versus clinical subtypes for breast cancer among 621 patients from the EORTC 10041/BIG 3–04 (MINDACT) trial." In Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p3-05-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Валь, Н. С., and М. А. Степанова. "Управление качеством в специализированном противотуберкулезном учреждении на основе ISO 9001." In ТЕНДЕНЦИИ РАЗВИТИЯ НАУКИ И ОБРАЗОВАНИЯ. НИЦ «Л-Журнал», 2017. http://dx.doi.org/10.18411/lj-30-04-2017-3-09.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Catalytic and Oxidative Behaviour of Silicon Carbide based Materials for Thermal Protection Materials." In 55th International Astronautical Congress of the International Astronautical Federation, the International Academy of Astronautics, and the International Institute of Space Law. Reston, Virigina: American Institute of Aeronautics and Astronautics, 2004. http://dx.doi.org/10.2514/6.iac-04-i.3.a.09.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Analysis of the Martian Ionosphere and Thermosphere Environment from Measurements of the ESA Mars Express Spacecraft." In 55th International Astronautical Congress of the International Astronautical Federation, the International Academy of Astronautics, and the International Institute of Space Law. Reston, Virigina: American Institute of Aeronautics and Astronautics, 2004. http://dx.doi.org/10.2514/6.iac-04-q.3.a.09.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Advanced Tool Set for the MATE�D : Initial Results from Operational Use." In 55th International Astronautical Congress of the International Astronautical Federation, the International Academy of Astronautics, and the International Institute of Space Law. Reston, Virigina: American Institute of Aeronautics and Astronautics, 2004. http://dx.doi.org/10.2514/6.iac-04-u.3.b.09.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Balbueno, Melina Castilho de Souza, Jéssica Amancio Martins, and Cidéli de Paula Coelho. "TRATAMENTO COM MEDICAMENTOS DE ALTAS DILUIÇÕES EM CADELA COM PIOMETRA: RELATO DE CASO." In I Congresso On-line Nacional de Clínica Veterinária de Pequenos Animais. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/2399.

Full text
Abstract:
Introdução: Piometra é caracterizada por infecção bacteriana aguda ou crônica, com acúmulo de exsudato em lúmen uterino e é um diagnóstico muito comum em cadelas não castradas, especialmente em fase de meia idade e mais velhas. O principal tratamento recomendado é a ovariohisterectomia, por ser o método mais seguro e eficaz e em alguns casos o tratamento médico é uma alternativa. A homeopatia visa a homeostase do paciente, ou seja, o equilíbrio. Seu efeito benéfico, sem efeitos colaterais é visualizado em diversos estudos com animais, assim como estudos in vitro. Objetivo: O presente trabalho tem como objetivo relatar um caso clínico de uma cadela com piometra tratada com medicamentos de altas diluições. Relato de caso: Uma cadela, sem raça definida, de 8 anos de idade, com 16,5 kg de peso, foi atendida dia 18/03/2021 com queixa de anorexia, aumento de circunferência abdominal, êmese e hematoquezia. No hemograma observou-se leucocitose discreta e recomendou-se realização de ultrassonografia abdominal, realizada dia 22/03/2021, na qual diagnosticou cornos uterinos com dimensões aumentadas, medindo aproximadamente 1,59 cm de diâmetro com conteúdo intraluminal, compatível com piometra, além disso, havia imagens compatíveis com neoplasia em fígado e baço. Diante das alterações diagnosticadas, optou-se pelo tratamento homeopático com Caulophylum 6 cH, 4 glóbulos, 4 vezes ao dia e Pulsatilla nigricans 12 cH, 4 glóbulos, 3 vezes ao dia, ambos por via oral. Após 4 dias do tratamento foi realizado o acompanhamento ultrassonográfico que diagnosticou discreta redução na dimensão dos cornos uterinos, medindo 1,28 cm de diâmetro, optou-se pela continuidade do tratamento, Caulophylum 6 cH, 4 glóbulos, 3 vezes ao dia e Pulsatilla nigricans 12 cH, 4 glóbulos, 2 vezes ao dia. Dia 09/04/2021 foi realizado novamente o ultrassom abdominal que diagnosticou cornos uterinos com dimensões de 0,81 cm, considerados parâmetros normais para o porte e espécie avaliada. Conclusão: Concluiu-se que a terapia com altas diluições foi benéfica, apresentando melhora visível em ultrassom e evitando o procedimento cirúrgico de um animal com várias comorbidades associadas. A homeopatia é uma medicina antiga e promissora para tratamento de diversas doenças.
APA, Harvard, Vancouver, ISO, and other styles
8

Dezordi, Sadiomar Antonio, Liéges Schwendler Johann, Silvana Terezinha Winckler, and Reginaldo Pereira. "SUSTENTABILIDADE E INTERCONEXÕES À BIODIVERSIDADE: GESTÃO E CONTROLE DO SUS-SCROFA NO ESTADO DE SANTA CATARINA." In II Congresso On-line Internacional de Sustentabilidade. Revista Multidisciplinar de Educação e Meio Ambiente, 2021. http://dx.doi.org/10.51189/rema/2025.

Full text
Abstract:
Introdução: O termo sustentabilidade, idealizado pelo engenheiro e cientista alemão Hans Carl Von Carlowitz, recebe sentidos latinos como suportar, continuar, manter e sustentar. Na CF/88 é marco axiológico da solidariedade (art. 3º, I), esteio do art. 225 na garantia do direito humanofundamental ao equilibrio ecológico e à sadia qualidade de vida, abrangendo as dimensões ambiental, econônica e social. Por sua vez o termo biodiversidade é atribuído a Walter G. Rosen, no Fórum Nacional sobre Biodiversidade, ao abordar a destruição de habitats e extinção acelerada de espécies. A biodiversidade hierarquiza grandezas genéticas, de espécies e ecossistemas, integradas no conceito legal de meio ambiente do art. 3°, I, da lei fed. nº 6.938/81. Já o art. 225 da CF/88requer a preservação e restauração dos tão combalidosprocessos ecológicos essenciais e o manejo ecológico das espécies e ecossistemas; e, veda práticas de risco a funçãoecológica ou a extinção de espécies. Objetivo: Analisar aatuação pública e resultados da Polícia Militar Ambiental catarinense (PMA), de gestão e controle dos impactosnegativos da espécie invasora Sus-scrofa. Material e métodos: Análise legislativa e bibliográfica, associada a estudo de caso, focalizando no construtivismo social e, abordagem qualitativa e quantitativa. Resultados: Docontexto e normas acima, dentre outras, especialmente pela ordem da Port. PMA nº 04/2010 e a Portaria SAR nº 20/2010 (reconhecido potencial de danosidade da invasora espécie Sus-scrofa), integraliza sim a PMA, pelo poder de polícia administrativa, efetiva e pioneira gestão, que em 2011/2012concedeu 22 autorizações de captura, manejo e abate no oeste catarinense, resultando no controle populacional de 237 animais (134 machos e 103 fêmeas), atendidas 07 propriedades nos municípios de Água Doce (09), Passos Maia (104) e Ponte Serrada (124). Conclusão: Obtidos os escoposcomo assente os resultados, demostra-se que a inovadora atuação da PMA catarinense, com tangível efetividade, gestão e controle do Sus-scrofa, sendo medida de sustentabilidade em interconexão à preservação da biodiversidade.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic '621.3 (09) (04)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography